Daniel R. Passeri

Executive

Chairman & CEO

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 1 buy · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (3 ops.)

€80k

▼ Sales (0 ops.)

—

Latest filing published 18 Dec 2024 for Cue Biopharma, Inc., €29k. Read the official filing

Filing timeline

BuySale

Daniel R. Passeri

Insider track record

Disclosed buys

Disclosed sells

T+90 hit rate

T+90 mean return

-22.6%

Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.

Signal history

Daniel R. Passeri: trading record in brief

Daniel R. Passeri, listed as chief executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Cue Biopharma, Inc. and Curis Inc. Over a trading history stretching from 6 January 2016 to 16 December 2024, the count stands at 6 filings.

No open-market sale appears; the market trades are 3 purchases worth €80k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 3 option exercises. In 2024 alone, the filings show 1 purchase and no sales.

A typical purchase (the median) is worth €29k. The 3 purchases reviewed show no overlap with other insiders buying the same stock within a month.

The record was last updated on 18 December 2024 with an open-market purchase (€29k) in Cue Biopharma, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.